A Phase 3 interventional study of Ibuprofen/Caffeine and Ibuprofen in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-04-08.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 8th largest by enrollment, is one of 8 that started in 2017, is one of 22 in phase 3, and was the 53rd registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 374 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 21st largest by enrollment of the 71 interventional ones that give a count, is the only one that started in 2017, is one of 28 in phase 3, and was the 72nd registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.
The purpose of this study is to assess the analgesic efficacy of a fixed dose combination of ibuprofen/caffeine compared to ibuprofen alone and also to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) determined by the Investigator to place the subject at increased risk including the presence or history within 2 years of screening of the following medical conditions/disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
Drug: Ibuprofen/Caffeine
Ibuprofen 400 mg
Drug: Ibuprofen
Placebo comparator
Drug: Placebo
Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen
SPRID 0-8: time-weighted sum of PRID scores from 0 to 8 hours. PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Numerical pain severity rating (NPSR) scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible SPRID 0-8 score range: -80 to 112, higher scores = more improvement in pain.
Time frame: From 0 to 8 hours post-dose on Day 1
Time Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 2 (SPRID 0-2), 0 to 4 (SPRID 0-4), 0 to 6 (SPRID 0-6) and 0 to 8 Hours Post-dose (SPRID 0-8)
SPRID 0-2, SPRID 0-4, SPRID 0-6, SPRID 0-8: time-weighted sum of PRID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours respectively. PRID at each post-dose time point = PID + PRR. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on 5-point scale: 0=none, 1=a little, 2=some, 3=a lot, 4=complete; higher scores=more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on 11-point scale: range from 0=no pain to 10=worst possible pain; higher scores=worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value=greater improvement. Score range for: SPRID 0-2= -20 to 28; SPRID 0-4= -40 to 56; SPRID 0-6= -60 to 84; SPRID 0-8= -80 to 112. Higher SPRID scores=more improvement in pain.
Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Time Weighted Sum of Pain Intensity Difference Scores From 0 to 2 Hours (SPID 0-2), 0 to 4 (SPID 0-4), 0 to 6 (SPID 0-6) and 0 to 8 Hours Post-dose (SPID 0-8)
SPID 0-2, SPID 0-4, SPID 0-6, SPID 0-8: time-weighted sum of PID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: score range from 0 = no pain to 10 = worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible range: SPID 0-2 = -20 to 20; SPID 0-4 = -40 to 40; SPID 0-6 = -60 to 60; SPID 0-8 = -80 to 80. Higher SPID scores = more improvement in pain.
Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Time Weighted Sum of Pain Relief Rating Scores From 0 to 2 (TOTPAR 0-2), 0 to 4 (TOTPAR 0-4), 0 to 6 (TOTPAR 0-6) and 0 to 8 Hours Post-dose (TOTPAR 0-8)
TOTPAR 0-2, TOTPAR 0-4, TOTPAR 0-6, TOTPAR 0-8: time-weighted sum of PRR scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. PRR score: at each post-dose time point participants answered to the question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Overall possible range: TOTPAR 0-2 = 0 to 8; TOTPAR 0-4 = 0 to 16; TOTPAR 0-6 = 0 to 24; TOTPAR 0-8 = 0 to 32. Higher TOTPAR scores = more improvement in pain.
Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Sum of Pain Relief Rating and Pain Intensity Difference (PRID) Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. At a single post-dose time point overall possible range for PRID score: -10 to 14, higher scores = more improvement in pain.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose on Day 1
Pain Relief Rating Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1
Pain Intensity Difference Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a single post-dose time point: -10 to 10, higher positive value = greater improvement in pain.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1
Time to Onset of Achieving Meaningful Relief
When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "meaningful relief" at the moment when they first experienced meaningful relief, that is, when the relief from the pain was meaningful to them. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).
Time frame: Up to 8 hours post-dose on Day 1
Time to Onset of First Perceptible Relief
When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "first perceptible relief" at the moment when they first began to feel any pain relieving effect. It was when they first felt a little/noticeable pain relief. It did not mean that they felt completely better (though they might), but when they first felt any difference in pain that they had at present. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).
Time frame: Up to 8 hours post-dose on Day 1
Time to Treatment Failure
Treatment failure was defined as time to first dose of rescue medication or study discontinuation of the participants due to lack of efficacy.
Time frame: Up to 8 hours post dose on Day 1
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. AEs are classified according to severity in 3 categories as mild (did not interfere with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).
Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Number of Participants With Treatment Emergent Treatment Related Adverse Events (AEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. Relatedness of an AE to study drug was assessed by investigator.
Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Number of Participants With Clinically Significant Vital Signs Abnormalities
Vital signs included: heart rate, blood pressure, respiratory rate, and temperature. Normal range for the vital signs were: systolic blood pressure 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure 60 to 90 mmHg, heart rate 50 to 110 beats per minute, respiratory rate 12 to 22 breaths per minute, and oral temperature 97.0 to 99.6 Fahrenheit (F). Value for vital signs outside the normal range was consider as abnormal. Clinical significance of vital signs abnormalities was determined at the investigator's discretion.
Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Number of Participants Who Used Concomitant Medications, and Rescue Medications
Rescue medication: participants who did not experience adequate relief after the 1 hour (post study drug dose) evaluation were given tramadol hydrochloride 50 to 100 mg orally or codeine sulfate 15 to 60 mg orally, based on the discretion of the Investigator, as rescue medication. If needed, 2 additional doses of rescue medications based on the discretion of the Investigator at the study center was given. Total maximum dose of tramadol was 300 mg and of codeine sulfate was 180 mg. Concomitant medication: medication received by participant other than study medication and rescue medication.
Time frame: Day 1
Number of Participants Who Used Medications Prior to This Study
In this outcome measure number of participants who were using any type of medications, prior to start of the study were reported.
Time frame: At Screening
| Milestone | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Started | 161 | 161 | 52 |
| Completed | 160 | 159 | 51 |
| Not completed | 1 | 2 | 1 |
| Withdrew: Participants unable to swallow capsule | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
SPRID 0-8: time-weighted sum of PRID scores from 0 to 8 hours. PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Numerical pain severity rating (NPSR) scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible SPRID 0-8 score range: -80 to 112, higher scores = more improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg |
|---|---|---|
| Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen | 55.5 ± 1.8 | 52.8 ± 1.8 |
SPRID 0-2, SPRID 0-4, SPRID 0-6, SPRID 0-8: time-weighted sum of PRID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours respectively. PRID at each post-dose time point = PID + PRR. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on 5-point scale: 0=none, 1=a little, 2=some, 3=a lot, 4=complete; higher scores=more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on 11-point scale: range from 0=no pain to 10=worst possible pain; higher scores=worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value=greater improvement. Score range for: SPRID 0-2= -20 to 28; SPRID 0-4= -40 to 56; SPRID 0-6= -60 to 84; SPRID 0-8= -80 to 112. Higher SPRID scores=more improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| SPRID 0-2 | 13.3 ± 0.4 | 12.2 ± 0.4 | 2.2 ± 0.7 |
| SPRID 0-4 | 30.0 ± 0.8 | 28.5 ± 0.8 | 6.0 ± 1.5 |
| SPRID 0-6 | 44.5 ± 1.3 | 42.1 ± 1.3 | 10.2 ± 2.3 |
| SPRID 0-8 | 55.5 ± 1.8 | 52.8 ± 1.8 | 14.6 ± 3.3 |
SPID 0-2, SPID 0-4, SPID 0-6, SPID 0-8: time-weighted sum of PID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: score range from 0 = no pain to 10 = worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible range: SPID 0-2 = -20 to 20; SPID 0-4 = -40 to 40; SPID 0-6 = -60 to 60; SPID 0-8 = -80 to 80. Higher SPID scores = more improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| SPID 0-2 | 8.7 ± 0.3 | 8.0 ± 0.3 | 1.2 ± 0.5 |
| SPID 0-4 | 19.9 ± 0.6 | 18.8 ± 0.6 | 3.5 ± 1.0 |
| SPID 0-6 | 29.5 ± 0.9 | 27.7 ± 0.9 | 6.1 ± 1.6 |
| SPID 0-8 | 36.6 ± 1.3 | 34.6 ± 1.3 | 8.8 ± 2.3 |
TOTPAR 0-2, TOTPAR 0-4, TOTPAR 0-6, TOTPAR 0-8: time-weighted sum of PRR scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. PRR score: at each post-dose time point participants answered to the question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Overall possible range: TOTPAR 0-2 = 0 to 8; TOTPAR 0-4 = 0 to 16; TOTPAR 0-6 = 0 to 24; TOTPAR 0-8 = 0 to 32. Higher TOTPAR scores = more improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| TOTPAR 0-2 | 4.6 ± 0.1 | 4.2 ± 0.1 | 1.0 ± 0.2 |
| TOTPAR 0-4 | 10.2 ± 0.3 | 9.7 ± 0.3 | 2.5 ± 0.5 |
| TOTPAR 0-6 | 15.0 ± 0.4 | 14.4 ± 0.4 | 4.1 ± 0.7 |
| TOTPAR 0-8 | 18.8 ± 0.6 | 18.2 ± 0.6 | 5.8 ± 1.0 |
PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. At a single post-dose time point overall possible range for PRID score: -10 to 14, higher scores = more improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| 0.25 hour | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.2 |
| 0.5 hour | 3.3 ± 0.2 | 3.3 ± 0.2 | 1.0 ± 0.4 |
| 1 hour | 7.2 ± 0.2 | 6.5 ± 0.2 | 1.1 ± 0.4 |
| 1.5 hour | 8.5 ± 0.2 | 7.7 ± 0.2 | 1.1 ± 0.4 |
| 2 hour | 8.9 ± 0.2 | 8.3 ± 0.2 | 1.3 ± 0.4 |
| 3 hour | 8.7 ± 0.2 | 8.3 ± 0.2 | 1.8 ± 0.4 |
| 4 hour | 8.1 ± 0.3 | 8.0 ± 0.3 | 2.0 ± 0.5 |
| 5 hour | 7.6 ± 0.3 | 7.3 ± 0.3 | 2.1 ± 0.5 |
| 6 hour | 6.9 ± 0.3 | 6.4 ± 0.3 | 2.1 ± 0.5 |
| 7 hour | 5.7 ± 0.3 | 5.6 ± 0.3 | 2.2 ± 0.6 |
| 8 hour | 5.2 ± 0.3 | 5.0 ± 0.3 | 2.2 ± 0.6 |
PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| 0.25 hour | 0.4 ± 0.0 | 0.4 ± 0.0 | 0.3 ± 0.1 |
| 0.5 hour | 1.3 ± 0.1 | 1.2 ± 0.1 | 0.5 ± 0.1 |
| 1 hour | 2.5 ± 0.1 | 2.3 ± 0.1 | 0.5 ± 0.1 |
| 1.5 hour | 2.8 ± 0.1 | 2.6 ± 0.1 | 0.5 ± 0.1 |
| 2 hour | 3.0 ± 0.1 | 2.8 ± 0.1 | 0.6 ± 0.1 |
| 3 hour | 2.9 ± 0.1 | 2.8 ± 0.1 | 0.7 ± 0.1 |
| 4 hour | 2.7 ± 0.1 | 2.7 ± 0.1 | 0.8 ± 0.1 |
| 5 hour | 2.6 ± 0.1 | 2.5 ± 0.1 | 0.8 ± 0.2 |
| 6 hour | 2.3 ± 0.1 | 2.2 ± 0.1 | 0.8 ± 0.2 |
| 7 hour | 2.0 ± 0.1 | 2.0 ± 0.1 | 0.9 ± 0.2 |
| 8 hour | 1.8 ± 0.1 | 1.8 ± 0.1 | 0.9 ± 0.2 |
NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a single post-dose time point: -10 to 10, higher positive value = greater improvement in pain.
| units on a scale | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| 0.25 hour | 0.4 ± 0.1 | 0.5 ± 0.1 | 0.4 ± 0.2 |
| 0.5 hour | 2.0 ± 0.2 | 2.1 ± 0.2 | 0.6 ± 0.3 |
| 1 hour | 4.7 ± 0.2 | 4.2 ± 0.2 | 0.6 ± 0.3 |
| 1.5 hour | 5.6 ± 0.2 | 5.1 ± 0.2 | 0.6 ± 0.3 |
| 2 hour | 5.9 ± 0.2 | 5.5 ± 0.2 | 0.7 ± 0.3 |
| 3 hour | 5.8 ± 0.2 | 5.5 ± 0.2 | 1.1 ± 0.3 |
| 4 hour | 5.4 ± 0.2 | 5.3 ± 0.2 | 1.2 ± 0.3 |
| 5 hour | 5.0 ± 0.2 | 4.8 ± 0.2 | 1.3 ± 0.3 |
| 6 hour | 4.5 ± 0.2 | 4.1 ± 0.2 | 1.2 ± 0.4 |
| 7 hour | 3.8 ± 0.2 | 3.6 ± 0.2 | 1.3 ± 0.4 |
| 8 hour | 3.4 ± 0.2 | 3.3 ± 0.2 | 1.3 ± 0.4 |
When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "meaningful relief" at the moment when they first experienced meaningful relief, that is, when the relief from the pain was meaningful to them. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).
| minutes | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Time to Onset of Achieving Meaningful Relief | 46.60 (42.82 to 49.15) | 52.25 (49.15 to 59.18) | NA (NA to NA) |
When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "first perceptible relief" at the moment when they first began to feel any pain relieving effect. It was when they first felt a little/noticeable pain relief. It did not mean that they felt completely better (though they might), but when they first felt any difference in pain that they had at present. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).
| minutes | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Time to Onset of First Perceptible Relief | 25.80 (21.93 to 29.42) | 24.52 (22.78 to 26.90) | NA (NA to NA) |
Treatment failure was defined as time to first dose of rescue medication or study discontinuation of the participants due to lack of efficacy.
| minutes | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Time to Treatment Failure | NA (NA to NA) | NA (NA to NA) | 310.00 (132.00 to 480.00) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. AEs are classified according to severity in 3 categories as mild (did not interfere with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).
| Participants | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Mild | 3 | 8 | 0 |
| Moderate | 12 | 7 | 8 |
| Severe | 0 | 0 | 0 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. Relatedness of an AE to study drug was assessed by investigator.
| Participants | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Number of Participants With Treatment Emergent Treatment Related Adverse Events (AEs) | 1 | 2 | 2 |
Vital signs included: heart rate, blood pressure, respiratory rate, and temperature. Normal range for the vital signs were: systolic blood pressure 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure 60 to 90 mmHg, heart rate 50 to 110 beats per minute, respiratory rate 12 to 22 breaths per minute, and oral temperature 97.0 to 99.6 Fahrenheit (F). Value for vital signs outside the normal range was consider as abnormal. Clinical significance of vital signs abnormalities was determined at the investigator's discretion.
| Participants | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 | 0 |
Rescue medication: participants who did not experience adequate relief after the 1 hour (post study drug dose) evaluation were given tramadol hydrochloride 50 to 100 mg orally or codeine sulfate 15 to 60 mg orally, based on the discretion of the Investigator, as rescue medication. If needed, 2 additional doses of rescue medications based on the discretion of the Investigator at the study center was given. Total maximum dose of tramadol was 300 mg and of codeine sulfate was 180 mg. Concomitant medication: medication received by participant other than study medication and rescue medication.
| Participants | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Concomitant Medications | 25 | 39 | 11 |
| Rescue Medications | 29 | 25 | 28 |
In this outcome measure number of participants who were using any type of medications, prior to start of the study were reported.
| Participants | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Used Medications Prior to This Study | 161 | 161 | 52 |
Collected over Screening up to Day 17 after the last dose of study drug (approximately maximum 48 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen 400 mg + Caffeine 100 mg | 0/161 (0%) | 0/161 (0%) | 15/161 (9.3%) |
| Ibuprofen 400 mg | 0/161 (0%) | 0/161 (0%) | 15/161 (9.3%) |
| Placebo | 0/52 (0%) | 0/52 (0%) | 8/52 (15.4%) |
| Event | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/161 | 4/161 | 7/52 |
| VomitingGastrointestinal disorders | 3/161 | 2/161 | 6/52 |
| Tooth infectionInfections and infestations | 0/161 | 1/161 | 1/52 |
| Viral infectionInfections and infestations | 0/161 | 0/161 | 1/52 |
| Postoperative wound infectionInfections and infestations | 0/161 | 2/161 | 0/52 |
| Upper respiratory tract infectionInfections and infestations | 0/161 | 2/161 | 0/52 |
| Alveolar osteitisInfections and infestations | 2/161 | 0/161 | 0/52 |
| Gilbert's syndromeCongenital, familial and genetic disorders | 0/161 | 1/161 | 0/52 |
| Vision blurredEye disorders | 0/161 | 1/161 | 0/52 |
| Aphthous ulcerGastrointestinal disorders | 0/161 | 1/161 | 0/52 |
Safety analysis set included all participants who received the study medication.
| Age, Continuous(years) | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 19.3 ± 3.03 | 19.1 ± 2.88 | 18.9 ± 2.93 | 19.1 ± 2.95 |
| Sex: Female, Male(Participants) | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 85 | 84 | 27 | 196 |
| Male | 76 | 77 | 25 | 178 |
| Ethnicity (NIH/OMB)(Participants) | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 19 | 26 | 8 | 53 |
| Not Hispanic or Latino | 142 | 135 | 44 | 321 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Ibuprofen 400 mg + Caffeine 100 mg | Ibuprofen 400 mg | Placebo | Total |
|---|---|---|---|---|
| White | 153 | 142 | 51 | 346 |
| Asian | 2 | 3 | 0 | 5 |
| Black or African American | 2 | 2 | 0 | 4 |
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 7 | 0 | 8 |
| Other | 2 | 6 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2017 to primary completion in Apr 2018, 5 months.
Results were first posted in Apr 2019, 1 year after primary completion.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 5 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Caffeine